Novartis FY2027 EPS Forecast Increased by Zacks Research

Key Points

• Zacks Research has increased its FY2027 earnings per share (EPS) estimate for Novartis to $10.13, up from a prior estimate of $10.08, while the current full-year EPS consensus is at $8.45.
• In its latest quarterly earnings report, Novartis surpassed analysts' expectations with an EPS of $2.42, exceeding the consensus estimate of $2.38.
• Analysts have mixed ratings for Novartis, with one "Strong Buy," one "Buy," five "Hold," and two "Sell" ratings, indicating a consensus rating of "Hold."

Novartis AG (NYSE:NVS - Free Report) - Investment analysts at Zacks Research increased their FY2027 earnings per share (EPS) estimates for shares of Novartis in a note issued to investors on Thursday, September 4th. Zacks Research analyst Team now expects that the company will earn $10.13 per share for the year, up from their prior forecast of $10.08. The consensus estimate for Novartis' current full-year earnings is $8.45 per share.

Novartis (NYSE:NVS - Get Free Report) last issued its quarterly earnings data on Thursday, July 17th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.38 by $0.04. Novartis had a return on equity of 41.08% and a net margin of 25.64%.The business had revenue of $14.05 billion during the quarter, compared to analyst estimates of $13.94 billion. During the same period in the prior year, the company posted $1.97 EPS. The business's revenue for the quarter was up 12.3% compared to the same quarter last year.

A number of other equities analysts have also issued reports on NVS. Morgan Stanley raised Novartis from an "underweight" rating to an "equal weight" rating and set a $123.00 price target for the company in a research note on Friday, August 8th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of Novartis in a research report on Thursday, August 21st. Finally, Wall Street Zen downgraded Novartis from a "strong-buy" rating to a "buy" rating in a research report on Friday, August 22nd. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Novartis presently has a consensus rating of "Hold" and a consensus target price of $124.33.

Novartis Stock Performance

Shares of NYSE NVS opened at $128.49 on Friday. The stock has a fifty day moving average price of $121.06 and a two-hundred day moving average price of $114.94. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.62 and a current ratio of 0.82. The firm has a market cap of $271.41 billion, a P/E ratio of 18.70, a PEG ratio of 1.80 and a beta of 0.63. Novartis has a 1 year low of $96.06 and a 1 year high of $129.21.

Institutional Investors Weigh In On Novartis

Hedge funds and other institutional investors have recently made changes to their positions in the business. GFG Capital LLC acquired a new stake in shares of Novartis in the second quarter valued at about $26,000. Nexus Investment Management ULC bought a new stake in shares of Novartis in the first quarter valued at about $25,000. WPG Advisers LLC bought a new stake in shares of Novartis in the first quarter valued at about $25,000. Tsfg LLC lifted its stake in shares of Novartis by 366.0% in the first quarter. Tsfg LLC now owns 233 shares of the company's stock valued at $26,000 after buying an additional 183 shares during the period. Finally, Legacy Investment Solutions LLC bought a new stake in shares of Novartis in the second quarter valued at about $30,000. 13.12% of the stock is owned by institutional investors and hedge funds.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.